Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(60%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_1
2
40%
Ph phase_2
2
40%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Completed1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)

Trials by Status

completed120%
active_not_recruiting120%
recruiting240%
terminated120%

Recent Activity

3 active trials
Showing 5 of 5
completedphase_2

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

NCT06390059
active_not_recruitingphase_1

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT03223103
recruitingnot_applicable

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

NCT06611345
recruitingphase_2

TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

NCT06353360
terminatedphase_1

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

NCT03705351

Clinical Trials (5)

Showing 5 of 5 trials
NCT06390059Phase 2

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Completed
NCT03223103Phase 1

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Active Not Recruiting
NCT06611345Not Applicable

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Recruiting
NCT06353360Phase 2

TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Recruiting
NCT03705351Phase 1

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5